Standardizing Comprehensive Biomarker Testing in Non-Small Cell Lung Cancer

While next-generation sequencing is recommended by the National Comprehensive Cancer Network for biomarker testing for all patients with advanced non-small cell lung cancer (NSCLC), uptake among community oncology programs and practices is suboptimal. To standardize comprehensive biomarker testing in patients with NSCLC, Oncology Hematology Care, Inc., developed and implemented a 1-year quality improvement (QI) project that included custom data reports and monitoring dashboards to ensure practice-wide adoption and sustainability across multiple clinic sites. After increasing biomarker testing rates from 68% to 92.7%, this QI project is now being scaled across the country through the US Oncology Network, McKesson as a best-practice initiative.

Guest:

Molly Mendenhall, RN, BSN

Director of Quality and Compliance

Oncology Hematology Care, Inc. (OHC)

Cincinnati, Ohio

“[On average] biomarking testing for patients with cancer is less than 50%. But with a shift towards personalized medicine, if we can implement and standardize this testing across the nation, we could provide targeted therapies, which have been shown to improve overall survival and quality of life.”

This podcast is part of a special series with the 2023 ACCC Innovator Award winners. For a deeper dive into this and other content that will help your team reimagine how care is delivered at your cancer program or practice, register today for the ACCC 40th National Oncology Conference, Oct. 4-6, in Austin Texas.

Resources:

[Video] Optimizing Advanced NSCLC Biomarker Testing, Treatment, and Management Virtual Summit

Biomarker Testing in Patients with Non-Small Cell Lung Cancer

NSCLC Biomarker Testing Roadmap Infographic

[Video] Optimizing Biomarker Testing through Precision Medicine Stewardship

A Financial Advocate’s Guide to Biomarker Testing

Paying for Biomarker Testing

[Podcast] Financial Barriers to Biomarker Testing

[Podcast] Biomarker Testing Advocacy